Shanghai Xiao Fang Pharmaceutical Co.,Ltd.

SHSE:603207 Stock Report

Market Cap: CN¥4.0b

Shanghai Xiao Fang PharmaceuticalLtd Past Earnings Performance

Past criteria checks 2/6

Shanghai Xiao Fang PharmaceuticalLtd has been growing earnings at an average annual rate of 8.1%, while the Pharmaceuticals industry saw earnings growing at 9.1% annually. Revenues have been growing at an average rate of 7.5% per year. Shanghai Xiao Fang PharmaceuticalLtd's return on equity is 16.5%, and it has net margins of 41.7%.

Key information

8.1%

Earnings growth rate

14.3%

EPS growth rate

Pharmaceuticals Industry Growth10.9%
Revenue growth rate7.5%
Return on equity16.5%
Net Margin41.7%
Last Earnings Update30 Sep 2024

Recent past performance updates

No updates

Recent updates

Revenue & Expenses Breakdown

How Shanghai Xiao Fang PharmaceuticalLtd makes and spends money. Based on latest reported earnings, on an LTM basis.


Earnings and Revenue History

SHSE:603207 Revenue, expenses and earnings (CNY Millions)
DateRevenueEarningsG+A ExpensesR&D Expenses
30 Sep 244721976319
31 Dec 234722046016
31 Dec 224571755614
31 Dec 214021269414
31 Dec 203611604011
31 Dec 193401424711

Quality Earnings: 603207 has a high level of non-cash earnings.

Growing Profit Margin: 603207's current net profit margins (41.7%) are lower than last year (42%).


Free Cash Flow vs Earnings Analysis


Past Earnings Growth Analysis

Earnings Trend: 603207's earnings have grown by 8.1% per year over the past 5 years.

Accelerating Growth: 603207's earnings growth over the past year (0.2%) is below its 5-year average (8.1% per year).

Earnings vs Industry: 603207 earnings growth over the past year (0.2%) exceeded the Pharmaceuticals industry -2.5%.


Return on Equity

High ROE: 603207's Return on Equity (16.5%) is considered low.


Return on Assets


Return on Capital Employed


Discover strong past performing companies